Swiss National Bank Portfolio holdings
The Swiss National Bank (SNB), founded in 1907 and headquartered in Zurich with an office in Bern, is Switzerland’s central bank, responsible for conducting monetary policy, issuing the Swiss franc, and ensuring price stability, while uniquely managing a massive investment portfolio. Unlike most central banks, the SNB is a joint-stock company with shares traded on the SIX Swiss Exchange, owned roughly 55% by public entities like cantons and 45% by private investors, yet it operates independently under federal oversight. It holds over $800 billion in foreign currency reserves as of late 2024—invested in global equities, bonds, and gold—to manage the franc’s value, famously intervening in markets to prevent excessive appreciation, as seen with the 2015 abandonment of the euro peg. Led by Chairman Thomas Jordan until his planned exit in September 2024, the SNB balances its dual role as a monetary authority and a significant global investor, influencing both Swiss and international financial stability.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Linde
LIN
|
+$303M |
| 2 |
General Dynamics
GD
|
+$147M |
| 3 |
Cigna
CI
|
+$95.5M |
| 4 |
CVS Health
CVS
|
+$85.5M |
| 5 |
Marathon Petroleum
MPC
|
+$52.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AET
Aetna Inc
AET
|
+$234M |
| 2 |
Northrop Grumman
NOC
|
+$218M |
| 3 |
ESRX
Express Scripts Holding Company
ESRX
|
+$170M |
| 4 |
PX
Praxair Inc
PX
|
+$168M |
| 5 |
COL
Rockwell Collins
COL
|
+$116M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.9% |
| 2 | Healthcare | 16.26% |
| 3 | Consumer Discretionary | 11.53% |
| 4 | Communication Services | 10.15% |
| 5 | Industrials | 9.58% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1226
Halozyme
HALO
$11.4B
| $3.36M | ﹤0.01% |
229,600
+3,600
| +2% | +$57.4K |
|
1227
Urban Edge Properties
UE
$2.78B
| $3.35M | ﹤0.01% |
201,609
+3,400
| +2% | +$67K |
|
1228
Cheesecake Factory
CAKE
$5.57B
| $3.35M | ﹤0.01% |
76,900
| – | – |
|
1229
Tanger
SKT
$4.42B
| $3.34M | ﹤0.01% |
165,400
| – | – |
|
|
QTS
1230
DELISTED
QTS REALTY TRUST, INC.
QTS
| $3.34M | ﹤0.01% |
90,183
+1,200
| +1% | +$47.6K |
|
1231
Diamondrock Hospitality Co
DRH
$2.51B
| $3.34M | ﹤0.01% |
367,500
+18,800
| +5% | +$194K |
|
1232
Signet Jewelers
SIG
$3.6B
| $3.33M | ﹤0.01% |
104,700
+1,900
| +2% | +$95.3K |
|
1233
Wingstop
WING
$3.1B
| $3.33M | ﹤0.01% |
51,800
+1,300
| +3% | +$85K |
|
1234
Pegasystems
PEGA
$5.51B
| $3.32M | ﹤0.01% |
139,000
+3,600
| +3% | +$94.4K |
|
1235
Zscaler
ZS
$30.4B
| $3.32M | ﹤0.01% |
+84,700
| New | +$3.2M |
|
1236
Commercial Metals
CMC
$7.98B
| $3.31M | ﹤0.01% |
206,900
+5,100
| +3% | +$95.1K |
|
|
MGP
1237
DELISTED
MGM Growth Properties LLC Class A common shares representing limited liability company interests
MGP
| $3.31M | ﹤0.01% |
125,401
+1,600
| +1% | +$44.7K |
|
1238
Fabrinet
FN
$20.3B
| $3.31M | ﹤0.01% |
64,440
-1,000
| -2% | -$47.9K |
|
|
IMMU
1239
DELISTED
Immunomedics Inc
IMMU
| $3.3M | ﹤0.01% |
231,250
+28,200
| +14% | +$560K |
|
1240
Enovis
ENOV
$1.48B
| $3.3M | ﹤0.01% |
91,624
-1,743
| -2% | -$81.3K |
|
1241
Acadia Pharmaceuticals
ACAD
$4.89B
| $3.29M | ﹤0.01% |
203,404
+30,000
| +17% | +$583K |
|
1242
National Vision
EYE
$1.51B
| $3.27M | ﹤0.01% |
116,100
+31,600
| +37% | +$1.2M |
|
1243
Azenta
AZTA
$1.49B
| $3.27M | ﹤0.01% |
124,900
+3,400
| +3% | +$99.3K |
|
|
ARI
1244
Apollo Commercial Real Estate
ARI
$886M
| $3.26M | ﹤0.01% |
195,739
+2,600
| +1% | +$48K |
|
|
GWB
1245
DELISTED
Great Western Bancorp, Inc.
GWB
| $3.26M | ﹤0.01% |
104,200
+1,800
| +2% | +$65.5K |
|
1246
Granite Construction
GVA
$5.41B
| $3.25M | ﹤0.01% |
80,800
+2,100
| +3% | +$95.9K |
|
1247
Agree Realty
ADC
$9.34B
| $3.25M | ﹤0.01% |
54,882
+900
| +2% | +$51.4K |
|
1248
LendingTree
TREE
$461M
| $3.24M | ﹤0.01% |
14,750
+700
| +5% | +$159K |
|
1249
Deluxe
DLX
$1.11B
| $3.24M | ﹤0.01% |
84,200
| – | – |
|
1250
Silgan Holdings
SLGN
$4.46B
| $3.23M | ﹤0.01% |
136,900
+3,300
| +2% | +$83K |
|
Similar funds
Swiss National Bank's Q4 2018 Portfolio in Review
As of Q4 2018, Swiss National Bank held 2,591 positions worth $78B, down 13% from $89.8B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Swiss National Bank's Q4 2018 filing shows 87 new, 1,610 increased, 323 reduced and 55 closed positions. Its largest new stake was Linde: 1,915,836 shares worth $299M. The largest sale was Aetna Inc, an estimated $234M.
By sector, the portfolio is most concentrated in Technology at 19% of assets, down from 20% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Swiss National Bank's largest Q4 2018 buy was Linde: 1,915,836 shares worth $299M.
- Swiss National Bank added most to Cigna in Q4 2018, an estimated $95.5M increase.
- Swiss National Bank's biggest Q4 2018 reduction was Dell, cutting an estimated $52.3M.
- Swiss National Bank fully exited Aetna Inc in Q4 2018, selling an estimated $234M.
- Swiss National Bank's ten largest holdings make up 18% of its $78B portfolio in Q4 2018.
- Swiss National Bank opened 87 new positions and closed 55 in Q4 2018.
- Swiss National Bank's portfolio value fell 13% quarter-over-quarter to $78B.
Based on Swiss National Bank's 13F filing for Q4 2018, filed 13 Feb 2019.